Abstract
Angiogenesis is a fundamental step in the development and progression of malignant tumors. Blockade of angiogenesis in preclinical models prevents the growth of tumor cells and therefore tumor progression. The VEGF pathway is considered to be the major regulator of angiogenesis in normal and malignant tissues. Bevacizumab is the only angiogenesis inhibitor currently approved for use in advanced nonsmall-cell lung cancer. A paclitaxel-based regimen in combination with bevacizumab is the only regimen that has demonstrated a survival advantage in comparison to standard chemotherapy in a Phase III trial. There is a lack of reliable prognostic or predictive biomarkers for selecting patients with nonsmall-cell lung cancer who would benefit from antiangiogenic therapy.
| Original language | English (US) |
|---|---|
| Title of host publication | Targeted Therapies for Non-Small-Cell Lung Cancer |
| Publisher | Future Medicine Ltd. |
| Pages | 35-45 |
| Number of pages | 11 |
| ISBN (Print) | 9781780840468, 9781780841236 |
| DOIs | |
| State | Published - Oct 1 2012 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
VEGF inhibitors. / Chavez, Ariel Lopez; Sandler, Alan.
Targeted Therapies for Non-Small-Cell Lung Cancer. Future Medicine Ltd., 2012. p. 35-45.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - VEGF inhibitors
AU - Chavez, Ariel Lopez
AU - Sandler, Alan
PY - 2012/10/1
Y1 - 2012/10/1
N2 - Angiogenesis is a fundamental step in the development and progression of malignant tumors. Blockade of angiogenesis in preclinical models prevents the growth of tumor cells and therefore tumor progression. The VEGF pathway is considered to be the major regulator of angiogenesis in normal and malignant tissues. Bevacizumab is the only angiogenesis inhibitor currently approved for use in advanced nonsmall-cell lung cancer. A paclitaxel-based regimen in combination with bevacizumab is the only regimen that has demonstrated a survival advantage in comparison to standard chemotherapy in a Phase III trial. There is a lack of reliable prognostic or predictive biomarkers for selecting patients with nonsmall-cell lung cancer who would benefit from antiangiogenic therapy.
AB - Angiogenesis is a fundamental step in the development and progression of malignant tumors. Blockade of angiogenesis in preclinical models prevents the growth of tumor cells and therefore tumor progression. The VEGF pathway is considered to be the major regulator of angiogenesis in normal and malignant tissues. Bevacizumab is the only angiogenesis inhibitor currently approved for use in advanced nonsmall-cell lung cancer. A paclitaxel-based regimen in combination with bevacizumab is the only regimen that has demonstrated a survival advantage in comparison to standard chemotherapy in a Phase III trial. There is a lack of reliable prognostic or predictive biomarkers for selecting patients with nonsmall-cell lung cancer who would benefit from antiangiogenic therapy.
UR - http://www.scopus.com/inward/record.url?scp=84957403725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957403725&partnerID=8YFLogxK
U2 - 10.2217/EBO.12.8
DO - 10.2217/EBO.12.8
M3 - Chapter
AN - SCOPUS:84957403725
SN - 9781780840468
SN - 9781780841236
SP - 35
EP - 45
BT - Targeted Therapies for Non-Small-Cell Lung Cancer
PB - Future Medicine Ltd.
ER -